Novartis AG
remibrutinib
chronic inducible urticaria
Date
TBD
Phase 3 readout · Date TBD estimated
What's at stake
Phase 3 trial results for remibrutinib in chronic inducible urticaria are due Date TBD. A clean hit validates the program; a miss can gap the stock down hard.
Primary source
· SEC 6-K
verified 13h ago
“compelling Phase III results for remibrutinib in chronic inducible urticaria”